Trial Profile
A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- Sponsors Rigel Pharmaceuticals
- 22 Oct 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 07 May 2015 New trial record